Drug Profile


Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; Columbia University; Genentech; Groupe Francophone des Myelodysplasies; John Hopkins University; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Hepatocellular carcinoma; Myeloproliferative disorders; Ovarian cancer; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer
  • Phase I Malignant melanoma; Small cell lung cancer
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 25 Jul 2017 Memorial Sloan Kettering Cancer Center in collaboration with Merck, Astex Pharmaceuticals and Mirati Therapeutics plans a phase I trial of guadecitabine in combination with mocetinostat and pembrolizumab for Non small cell lung cancer (Late stage disease, Second line therapy, Combination therapy) in USA, in July 2017 (NCT03220477)
  • 30 Jun 2017 National Cancer Institute plans a phase I/II trial for Fallopian tube cancer (Recurrent, Second-line therapy or greater, Combination therapy),Ovarian cancer (Recurrent, Second-line therapy or greater, Combination therapy) and Peritoneal cancer (Recurrent, Second-line therapy or greater, Combination therapy) in USA (NCT03206047)
  • 12 Jun 2017 Fox Chase Cancer Center plans a phase II trial for Urothelial cancer(Recurrent, Late-stage disease, Second-line therapy or greater, Combination therapy, Metastatic disease) (NCT03179943)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top